Oral drug elraglusib aims to tame advanced solid tumors

NCT ID NCT07714395

Not yet recruiting Disease control Sponsor: Actuate Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs of anti-tumor activity. Participants take elraglusib tablets once daily, and researchers monitor side effects, drug levels, and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elraglusib oral tablets
What this could lead to: If successful, this could point toward a new oral treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is not yet known if elraglusib will effectively shrink tumors or improve survival. Side effects may limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR

More trials for these conditions

Other studies related to the condition(s) this trial covers.